✨Generative AI is poised to transform nearly every aspect of the life sciences industry – but success at scale hinges on a clear gen AI strategy, dedicated budget, and custom solutions. In this new article, my McKinsey colleagues surveyed more than 100 pharmaceutical, biotech, and medical-device leaders to better understand their activity related to commercial applications of gen AI. Here are 4 insights they uncovered: ☑ At-scale adoption remains limited ☑ The early impact is promising ☑ Purposeful prioritization is a major differentiator ☑ Companies plan to build their own gen AI capabilities The biggest takeaway of all? Commercial life sciences leaders with a defined gen AI strategy and dedicated budgets were twice as likely to see meaningful results than those without them. Learn more here: https://lnkd.in/ddBmCy7i #commerciallifesciences #lifesciences #genAI #innovation

✨Generative AI is poised to transform nearly every aspect of the life sciences industry – but success at scale hinges on a clear gen AI strategy, dedicated budget, and custom solutions. In this new article, my McKinsey colleagues surveyed more than 100 pharmaceutical, biotech, and medical-device leaders to better understand their activity related to commercial applications of gen AI. Here are 4 insights they uncovered: ☑ At-scale adoption remains limited ☑ The early impact is promising ☑ Purposeful prioritization is a major differentiator ☑ Companies plan to build their own gen AI capabilities The biggest takeaway of all? Commercial life sciences leaders with a defined gen AI strategy and dedicated budgets were twice as likely to see meaningful results than those without them. Learn more here: https://lnkd.in/d3tUgGvy #commerciallifesciences #lifesciences #genAI #innovation

✨Generative AI is poised to transform nearly every aspect of the life sciences industry – but success at scale hinges on a clear gen AI strategy, dedicated budget, and custom solutions. In this new article, my McKinsey colleagues surveyed more than 100 pharmaceutical, biotech, and medical-device leaders to better understand their activity related to commercial applications of gen AI. Here are 4 insights they uncovered: ☑ At-scale adoption remains limited ☑ The early impact is promising ☑ Purposeful prioritization is a major differentiator ☑ Companies plan to build their own gen AI capabilities The biggest takeaway of all? Commercial life sciences leaders with a defined gen AI strategy and dedicated budgets were twice as likely to see meaningful results than those without them. Learn more here: https://lnkd.in/dhTGZzrU #commerciallifesciences #lifesciences #genAI #innovation

✨Generative AI is poised to transform nearly every aspect of the life sciences industry – but success at scale hinges on a clear gen AI strategy, dedicated budget, and custom solutions. In this new article, my McKinsey colleagues surveyed more than 100 pharmaceutical, biotech, and medical-device leaders to better understand their activity related to commercial applications of gen AI. Here are 4 insights they uncovered: ☑ At-scale adoption remains limited ☑ The early impact is promising ☑ Purposeful prioritization is a major differentiator ☑ Companies plan to build their own gen AI capabilities The biggest takeaway of all? Commercial life sciences leaders with a defined gen AI strategy and dedicated budgets were twice as likely to see meaningful results than those without them. Learn more here: https://lnkd.in/eQFkTNZX #commerciallifesciences #lifesciences #genAI #innovation

✨Generative AI is poised to transform nearly every aspect of the life sciences industry – but success at scale hinges on a clear gen AI strategy, dedicated budget, and custom solutions. In this new article, my McKinsey colleagues surveyed more than 100 pharmaceutical, biotech, and medical-device leaders to better understand their activity related to commercial applications of gen AI. Here are 4 insights they uncovered: ☑ At-scale adoption remains limited ☑ The early impact is promising ☑ Purposeful prioritization is a major differentiator ☑ Companies plan to build their own gen AI capabilities The biggest takeaway of all? Commercial life sciences leaders with a defined gen AI strategy and dedicated budgets were twice as likely to see meaningful results than those without them. Learn more here: https://lnkd.in/gYqnV--Y #commerciallifesciences #lifesciences #genAI #innovation

✨Generative AI is poised to transform nearly every aspect of the life sciences industry – but success at scale hinges on a clear gen AI strategy, dedicated budget, and custom solutions. In this new article, my McKinsey colleagues surveyed more than 100 pharmaceutical, biotech, and medical-device leaders to better understand their activity related to commercial applications of gen AI. Here are 4 insights they uncovered: ☑ At-scale adoption remains limited ☑ The early impact is promising ☑ Purposeful prioritization is a major differentiator ☑ Companies plan to build their own gen AI capabilities The biggest takeaway of all? Commercial life sciences leaders with a defined gen AI strategy and dedicated budgets were twice as likely to see meaningful results than those without them. Learn more here: https://lnkd.in/gcwhptrZ #commerciallifesciences #lifesciences #genAI #innovation

✨Generative AI is poised to transform nearly every aspect of the life sciences industry – but success at scale hinges on a clear gen AI strategy, dedicated budget, and custom solutions. In this new article, my McKinsey colleagues surveyed more than 100 pharmaceutical, biotech, and medical-device leaders to better understand their activity related to commercial applications of gen AI. Here are 4 insights they uncovered: ☑ At-scale adoption remains limited ☑ The early impact is promising ☑ Purposeful prioritization is a major differentiator ☑ Companies plan to build their own gen AI capabilities The biggest takeaway of all? Commercial life sciences leaders with a defined gen AI strategy and dedicated budgets were twice as likely to see meaningful results than those without them. Learn more here: https://lnkd.in/eHrFENnX #commerciallifesciences #lifesciences #genAI #innovation

✨Generative AI is poised to transform nearly every aspect of the life sciences industry – but success at scale hinges on a clear gen AI strategy, dedicated budget, and custom solutions. In this new article, my McKinsey colleagues surveyed more than 100 pharmaceutical, biotech, and medical-device leaders to better understand their activity related to commercial applications of gen AI. Here are 4 insights they uncovered: ☑ At-scale adoption remains limited ☑ The early impact is promising ☑ Purposeful prioritization is a major differentiator ☑ Companies plan to build their own gen AI capabilities The biggest takeaway of all? Commercial life sciences leaders with a defined gen AI strategy and dedicated budgets were twice as likely to see meaningful results than those without them. Learn more here: https://lnkd.in/eEwGQcbF #commerciallifesciences #lifesciences #genAI #innovation

✨Generative AI is poised to transform nearly every aspect of the life sciences industry – but success at scale hinges on a clear gen AI strategy, dedicated budget, and custom solutions. In this new article, my McKinsey colleagues surveyed more than 100 pharmaceutical, biotech, and medical-device leaders to better understand their activity related to commercial applications of gen AI. Here are 4 insights they uncovered: ☑ At-scale adoption remains limited ☑ The early impact is promising ☑ Purposeful prioritization is a major differentiator ☑ Companies plan to build their own gen AI capabilities The biggest takeaway of all? Commercial life sciences leaders with a defined gen AI strategy and dedicated budgets were twice as likely to see meaningful results than those without them. Learn more here: https://lnkd.in/eY77nrXS #commerciallifesciences #lifesciences #genAI #innovation

✨Generative AI is poised to transform nearly every aspect of the life sciences industry – but success at scale hinges on a clear gen AI strategy, dedicated budget, and custom solutions. In this new article, my McKinsey colleagues surveyed more than 100 pharmaceutical, biotech, and medical-device leaders to better understand their activity related to commercial applications of gen AI. Here are 4 insights they uncovered: ☑ At-scale adoption remains limited ☑ The early impact is promising ☑ Purposeful prioritization is a major differentiator ☑ Companies plan to build their own gen AI capabilities The biggest takeaway of all? Commercial life sciences leaders with a defined gen AI strategy and dedicated budgets were twice as likely to see meaningful results than those without them. Learn more here: https://lnkd.in/gSURxbMP #commerciallifesciences #lifesciences #genAI #innovation